Dataset Information

Reduction in perceived stress as a migraine trigger: testing the "let-down headache" hypothesis.

ABSTRACT:

Objective

To test whether level of perceived stress and reductions in levels of perceived stress (i.e., "let-down") are associated with the onset of migraine attacks in persons with migraine.

Methods

Patients with migraine from a tertiary headache center were invited to participate in a 3-month electronic diary study. Participants entered data daily regarding migraine attack experience, subjective stress ratings, and other data. Stress was assessed using 2 measures: the Perceived Stress Scale and the Self-Reported Stress Scale. Logit-normal, random-effects models were used to estimate the odds ratio for migraine occurrence as a function of level of stress over several time frames.

Results

Of 22 enrolled participants, 17 (median age 43.8 years) completed >30 days of diaries, yielding 2,011 diary entries including 110 eligible migraine attacks (median 5 attacks per person). Level of stress was not generally associated with migraine occurrence. However, decline in stress from one evening diary to the next was associated with increased migraine onset over the subsequent 6, 12, and 18 hours, with odds ratios ranging from 1.5 to 1.9 (all p values < 0.05) for the Perceived Stress Scale. Decline in stress was associated with migraine onset after controlling for level of stress for all time points. Findings were similar using the Self-Reported Stress Scale.

Conclusions

Reduction in stress from one day to the next is associated with migraine onset the next day. Decline in stress may be a marker for an impending migraine attack and may create opportunities for preemptive pharmacologic or behavioral interventions.

SUBMITTER: Lipton RB

PROVIDER: S-EPMC4001194 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Reduction in perceived stress as a migraine trigger: testing the "let-down headache" hypothesis.

Lipton Richard B RB Buse Dawn C DC Hall Charles B CB Tennen Howard H Defreitas Tiffani A TA Borkowski Thomas M TM Grosberg Brian M BM Haut Sheryl R SR

Neurology 20140326 16

<h4>Objective</h4>To test whether level of perceived stress and reductions in levels of perceived stress (i.e., "let-down") are associated with the onset of migraine attacks in persons with migraine.<h4>Methods</h4>Patients with migraine from a tertiary headache center were invited to participate in a 3-month electronic diary study. Participants entered data daily regarding migraine attack experience, subjective stress ratings, and other data. Stress was assessed using 2 measures: the Perceived ...[more]

PMID: 24670889

Similar Datasets

Project description:ObjectiveTo evaluate the impact of fremanezumab on the severity and duration of remaining migraine attacks in patients with chronic migraine (CM) or episodic migraine (EM).BackgroundFremanezumab is a fully humanized monoclonal antibody (IgGΔa) that selectively targets calcitonin gene-related peptide and is efficacious in reducing migraine frequency.MethodsThis exploratory post hoc analysis included data from three randomized, double-blind, 12-week, phase 3 studies (HALO CM, HALO EM, and FOCUS). In all three studies, patients with CM or EM were randomized 1:1:1 to receive subcutaneous quarterly fremanezumab (month 1/2/3: 675 mg/placebo/placebo), monthly fremanezumab (month 1/2/3: 675 mg [CM], 225 mg [EM]/225 mg/225 mg), or matched monthly placebo. Changes from baseline were evaluated in the proportion of headache days of at least moderate severity, peak severity of headache days, mean monthly headache hours (of any severity and at least moderate severity), and mean headache hours per headache day of any severity.ResultsA total of 2843 patients were randomized with 2823 patients included in the efficacy analyses across all studies (HALO CM, N = 1121; HALO EM, N = 865; FOCUS, N = 837). At study baseline, mean (standard deviation [SD]) monthly number of headache days rated moderate or severe in the quarterly fremanezumab, monthly fremanezumab, and placebo groups, respectively, were 13.2 (5.5), 12.8 (5.8), and 13.3 (5.8) in HALO CM; 7.2 (3.1), 6.8 (2.9), and 6.9 (3.1) in HALO EM; and 12.4 (5.8), 12.7 (5.8), and 12.8 (5.9) in FOCUS. Patients experienced significant least-squares mean (LSM; 95% confidence interval) percent reductions from baseline in monthly number of headache days rated moderate or severe during the 12 weeks: HALO CM, quarterly fremanezumab, 34.5% (-39.8, -29.2) and monthly fremanezumab, 36.2% (-41.4, -31.0) vs. placebo, 19.6% (-20.0, -14.3); HALO EM, quarterly fremanezumab, 40.7% (-47.8, -33.5) and monthly fremanezumab, 43.4% (-50.4, -36.3) vs. placebo, 17.9% (-24.9, -11.0); and FOCUS, quarterly fremanezumab, 36.5% (-41.9, -31.1) and monthly fremanezumab, 38.6% (-44.0, -33.3) vs. placebo, 3.5% (-8.9, 1.8); all p < 0.0001. At study baseline, mean (SD) number of monthly headache hours rated moderate or severe in the quarterly fremanezumab, monthly fremanezumab, and placebo groups, respectively, were 66.4 (58.8), 68.0 (53.9), and 68.5 (57.0) in HALO CM; 33.3 (25.4), 31.7 (23.7), and 31.6 (23.2) in HALO EM; and 59.2 (54.7), 64.3 (65.2), and 65.9 (70.2) in FOCUS. Significant reductions were observed in LSM (standard error) number of monthly headache hours of at least moderate severity: HALO CM, quarterly fremanezumab, 24.4 (2.5) and monthly fremanezumab, 26.4 (2.3) vs. placebo, 14.1 (2.5); HALO EM, quarterly fremanezumab, 14.5 (1.4) and monthly fremanezumab, 15.5 (1.3) vs. placebo, 8.1 (1.3); and FOCUS, quarterly fremanezumab, 16.8 (3.0) and monthly fremanezumab, 18.3 (3.0) vs. placebo, 2.3 (3.0); all p < 0.001.ConclusionThese analyses demonstrated that quarterly or monthly treatment with fremanezumab significantly reduced headache severity and duration in patients with CM or EM, including in patients with documented inadequate response to two to four prior migraine preventive medication classes.

Project description:High-spin trinuclear iron complex ((tbs)L)Fe3(thf) ([(tbs)L](6-) = [1,3,5-C6H9(NC6H4-o-NSi(t)BuMe2)3](6-)) (S = 6) facilitates 2 and 4e(-) reduction of NxHy type substrates to yield imido and nitrido products. Reaction of hydrazine or phenylhydrazine with ((tbs)L)Fe3(thf) yields triiron ?(3)-imido cluster ((tbs)L)Fe3(?(3)-NH) and ammonia or aniline, respectively. ((tbs)L)Fe3(?(3)-NH) has a similar zero-field (57)Fe Mössbauer spectrum compared to previously reported [((tbs)L)Fe3(?(3)-N)]NBu4, and can be directly synthesized by protonation of the anionic triiron nitrido with lutidinium tetraphenylborate. Deprotonation of the triiron parent imido ((tbs)L)Fe3(?(3)-NH) with lithium bis(trimethylsilyl)amide results in regeneration of the triiron nitrido complex capped with a thf-solvated Li cation [((tbs)L)Fe3(?(3)-N)]Li(thf)3. The lithium capped nitrido, structurally similar to the pseudo C3-symmetric triiron nitride with a tetrabutylammonium countercation, is rigorously C3-symmetric featuring intracore distances of Fe-Fe 2.4802(5) Å, Fe-N(nitride) 1.877(2) Å, and N(nitride)-Li 1.990(6) Å. A similar 2e(-) reduction of 1,2-diphenylhydrazine by ((tbs)L)Fe3(thf) affords ((tbs)L)Fe3(?(3)-NPh) and aniline. The solid state structure of ((tbs)L)Fe3(?(3)-NPh) is similar to the series of ?(3)-nitrido and -imido triiron complexes synthesized in this work with average Fe-Nimido and Fe-Fe bond lengths of 1.941(6) and 2.530(1) Å, respectively. Reductive N?N bond cleavage of azobenzene is also achieved in the presence of ((tbs)L)Fe3(thf) to yield triiron bis-imido complex ((tbs)L)Fe3(?(3)-NPh)(?(2)-NPh), which has been structurally characterized. Ligand redox participation has been ruled out, and therefore, charge balance indicates that the bis-imido cluster has undergone a 4e(-) metal based oxidation resulting in an (Fe(IV))(Fe(III))2 formulation. Cyclic voltammograms of the series of triiron clusters presented herein demonstrate that oxidation states up to (Fe(IV))(Fe(III))2 (in the case of [((tbs)L)Fe3(?(3)-N)]NBu4) are electrochemically accessible. These results highlight the efficacy of high-spin, polynuclear reaction sites to cooperatively mediate small molecule activation.

Dataset Information

Reduction in perceived stress as a migraine trigger: testing the "let-down headache" hypothesis.

Objective

Methods

Results

Conclusions

Publications

Reduction in perceived stress as a migraine trigger: testing the "let-down headache" hypothesis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure